Bio-Rad Labs (BIO) Tops Q3 EPS by 53c

Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $0.91, $0.53 better than the analyst estimate of $0.38. Revenue for the quarter came in at $535 million versus the consensus estimate of $508 million.

GUIDANCE:

Bio-Rad Labs sees Q4 2017 revenue of $615-625 million, versus the consensus of $633 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low
• CalPrivate Bank names Andra Frazier as chief credit officer